EGFR and non-small cell lung carcinoma: These findings suggest that recurrence rates were high in resected EGFR-positive NSCLC, yet 37% of patients with stage IB through IIIA were cured without adjuvant osimertinib, highlighting the need for individualized risk-profiling.